FDA grants special status for Biogen, Eisai Alzheimer treatment
Biogen Inc. and Eisai Co., Ltd. announced on Wednesday that the United States Food and Drug Administration (FDA) gave their lecanemab antibody treatment for Alzheimer’s disease the designation o…